Connect with us

Research

Antineoplaston can be used as an alternative treatment for cancer – part 1/2

Published

on

Antineoplaston can be used as an alternative treatment for cancer

Antineoplastons are a group of natural compounds that have been proposed as a treatment for cancer. The compounds were discovered by Dr. Stanislaw Burzynski, a Polish-American physician, who began studying them in the 1970s. Dr. Burzynski claims that antineoplastons can selectively target and kill cancer cells while leaving healthy cells intact. 

Antineoplastons are made from substances that are found naturally in the body, such as amino acids and peptides. They are administered orally or intravenously. According to Dr. Burzynski, antineoplastons work by restoring the balance of genetic regulation in cancer cells, which leads to cancer cell death. 

There have been several clinical trials of antineoplastons in patients with different types of cancer, including brain tumors, lung cancer, and breast cancer. Some of these trials have reported positive results, with patients showing improvement in their symptoms and tumor size reduction. However, many of the trials have been small and have not been conducted using rigorous scientific methods. 

The scientific community has been divided in their opinion on the effectiveness of antineoplastons as a cancer treatment. Some researchers have criticized the lack of rigorous scientific evidence supporting the use of antineoplastons, while others have pointed out the promising results seen in some of the trials. 

The U.S. Food and Drug Administration (FDA) has not approved antineoplastons as a cancer treatment. The FDA has instead approved a phase II clinical trial to evaluate the safety and effectiveness of antineoplastons in treating certain types of brain tumors. 

It’s worth mentioning that antineoplastons as a cancer treatment is considered as alternative or experimental therapy, and its use should be discussed with a doctor before making any decision. Also, it’s important to note that the FDA has not approved antineoplastons as a cancer treatment, and their safety and effectiveness have not been established. 

Antineoplastons are a group of natural compounds that have been proposed as a treatment for cancer. While there have been some reports of positive results in the treatment of cancer with antineoplastons, more rigorous scientific evidence is needed to establish their safety and effectiveness. It’s important to talk to a doctor before considering antineoplastons as a cancer treatment and to be aware that it is not approved by the FDA. 

Here is the link for part 2

 13,574 total views,  6 views today

Spread the love

Designer | Ideator | Thinker | Love Reading, Writing | Wildlife | Passionate about Learning New Stuff & Technologies. For suggestions and questions if you have any, then you can visit this link. (Disclaimer : My views are entirely my own and have nothing to do with any organisation)

Editor's Picks

A bioengineered kidney grown successfully, a medical breakthrough

Published

on

A bioengineered kidney grown successfully a medical breakthrough 1

Regenerative medicine is no longer limited to repairing tissues. It is moving toward building fully functional organs. One of the most exciting developments in this field is the bioengineering of kidney tissue that can filter blood and produce urine like fluid under laboratory conditions. While a transplant ready lab grown kidney does not yet exist, the science has moved far beyond theory.

This is not science fiction. It is the result of years of research across leading institutions such as Harvard University, University of California, Davis, and collaborative global biotech laboratories. Findings have appeared in peer reviewed platforms including BMC Nephrology and Nature Reviews Nephrology.

What it means, and where the science stands today

Chinese scientists in Shanghai have achieved a major breakthrough in regenerative medicine by successfully growing a functional human kidney in a lab that filters blood, balances electrolytes, and produces urine. Using stem cell-derived organoids and a biodegradable hydrogel scaffold, this bioengineered organ mimicked natural kidney function for over 60 hours, marking a significant step toward addressing the global donor shortage.

Key details of this achievement include:

Functionality: The lab-grown kidney functions similarly to a natural organ, capable of separating waste from blood and returning clean plasma.

Structure: Researchers utilized advanced tissue engineering, seeding stem cells onto a specialized scaffold to form crucial kidney structures, including nephrons.

Significance: While still in experimental stages, this technology could eventually provide transplantable organs that, being derived from a patient’s own cells, could eliminate the need for immune-suppressing drugs.

Performance: The organoid “assembloids” (combined nephron and collecting duct components) demonstrated the ability to respond to hormonal signals, adjusting water and salt retention, similar to a real kidney.

Future outlook: Though fully transplantable human kidneys are not yet in clinical use, this milestone brings the medical community closer to replacing dialysis and saving patients with chronic kidney disease.

That is an incredible milestone in regenerative medicine! While we’ve seen “organoids” (miniature, simplified versions of organs) for several years, moving toward a fully functional, lab-grown kidney represents a massive leap toward solving the global organ donor shortage

Why this specific breakthrough is such a game-changer and what the current “state of the science” looks like.

The engineering challenge

The kidney is one of the most complex organs to replicate because it isn’t just a filter; it’s a sophisticated chemical plant. To work, a lab-grown kidney must master three distinct phases: 

Filtration: Removing waste from the blood through the glomerulus.

Reabsorption: Taking back necessary nutrients and water so you don’t become dehydrated.

Excretion: Channelling the waste (urine) out of the body through a complex network of tubes. 

How scientists are doing it

Current breakthroughs generally rely on two primary methods: 

3D bioprinting: Using “bio-ink” made of living cells to print the organ’s structure layer by layer, including the intricate vascular system (blood vessels) needed to keep the tissue alive.

Decellularization: Taking an existing organ (like a pig kidney or a damaged human kidney), stripping away all the original cells to leave a “ghost scaffold” of connective tissue, and then “re-seeding” it with the patient’s own stem cells. 

The implications of a functional, urine-producing lab kidney are profound: 

No more rejection: Because the organ is grown from the patient’s own stem cells, the immune system recognizes it as “self,” potentially eliminating the need for lifelong immunosuppressant drugs.

End of dialysis: Dialysis is grueling and only performs about 10-15% of a normal kidney’s function. A bioengineered organ could restore a patient to near-full health.

The “Waiting List” problem: Thousands of people die every year waiting for a transplant. Lab-grown organs could eventually be produced “on demand.” 

The global kidney crisis

Chronic kidney disease affects more than 850 million people worldwide. Many patients progress to end stage renal disease, where survival depends on dialysis or kidney transplantation. Dialysis is life sustaining but not a cure. Transplantation is limited by donor shortages, long waiting lists, immune rejection, and lifelong immunosuppression.

The gap between demand and availability has driven scientists to explore organ regeneration, bioengineering, and stem cell technology as long term solutions.

What is a bioengineered kidney

A bioengineered kidney is not a single technique but a combination of advanced biological and engineering strategies. The goal is to recreate the kidney’s complex architecture and functionality.

The process typically involves three major components:

1. Stem cells

Stem cells are the body’s master repair cells. Researchers use pluripotent stem cells, often induced pluripotent stem cells derived from adult tissues, and guide them to differentiate into kidney specific cell types such as podocytes, tubular cells, and endothelial cells.

2. Scaffolds

A scaffold acts as the structural backbone of the organ. It can be:

  • A decellularized kidney from a donor organ, where all cells are removed but the extracellular matrix remains intact
  • A synthetic biodegradable framework engineered to mimic kidney architecture

The scaffold provides physical guidance for cells to organize properly.

3. 3D bioprinting

3D bioprinting allows researchers to precisely place cells and biomaterials layer by layer. This is critical for constructing nephrons, the functional filtering units of the kidney, along with tiny ducts and vascular channels that allow fluid flow.

What has actually been achieved

Several major milestones have already been demonstrated:

Kidney organoids

Researchers have successfully grown kidney organoids, miniature simplified kidney structures derived from stem cells. These organoids:

  • Develop nephron like units
  • Show filtration characteristics
  • Respond to toxins and drugs similarly to human kidneys

Although small and immature compared to a full organ, they represent a functional biological model.

Perfusable vascular systems

A major breakthrough has been the creation of perfusable channels within engineered tissue. Scientists have demonstrated that:

  • Engineered ducts can carry urine like fluid
  • Lab grown kidney structures can filter waste molecules under controlled conditions
  • Blood vessel networks can integrate with host circulation in animal studies

This is critical because without vascularization, no organ can survive after transplantation.

Bioartificial kidney devices

Parallel to organ growth research, implantable bioartificial kidney devices are under development. These combine silicon filtration membranes with living kidney cells to replicate natural filtration and reabsorption processes.

What it can do today

In laboratory and experimental settings, bioengineered kidney tissue can:

  • Filter blood like fluid
  • Produce urine like output
  • Mimic early stage kidney functions
  • Serve as a testing platform for drug toxicity
  • Model genetic kidney diseases

However, it is important to be clear, there is no fully transplant ready lab grown human kidney functioning independently inside a human patient yet.

What it solves

1. Solving organ shortage

A successful lab grown kidney would eliminate the dependency on donor organs.

2. Reducing rejection

If generated from a patient’s own stem cells, the risk of immune rejection could be dramatically reduced.

3. Transforming drug testing

Kidney organoids already provide more accurate platforms for studying nephrotoxicity compared to animal models.

4. Personalized medicine

Scientists can grow patient specific kidney tissue to study inherited kidney diseases and test targeted therapies.

The scientific challenges ahead

Despite remarkable progress, several major hurdles remain:

Scaling up

Current organoids are tiny. A full human kidney contains about one million nephrons. Replicating this complexity at full scale is extremely challenging.

Maturation

Lab grown tissues often resemble fetal stage kidneys. They must mature to adult functionality before clinical transplantation becomes viable.

Vascular integration

Although perfusion systems have improved, integrating a bioengineered kidney with full systemic circulation remains complex.

Long term stability

Researchers must demonstrate long term durability, filtration efficiency, hormonal regulation, and safety.

The role of leading research institutions

Research teams from Harvard University have pioneered stem cell differentiation protocols and organoid development. Scientists at University of California, Davis have contributed to regenerative scaffolding and translational research.

Findings published in journals such as BMC Nephrology and Nature Reviews Nephrology detail advances in nephron modeling, vascularization strategies, and regenerative engineering techniques.

This global collaboration underscores that the field is moving steadily forward, grounded in peer reviewed science.

Are we close to human transplants

Experts suggest that while organoids and bioengineered tissue are advancing rapidly, a fully functional transplant ready kidney may still require years of development and clinical testing.

The pathway typically includes:

  • Preclinical animal studies
  • Safety validation
  • Regulatory approval
  • Carefully monitored human trials

However, progress over the last decade has been faster than many predicted.

Kidney bioengineering represents a broader shift in medicine. The focus is moving from managing organ failure to rebuilding organs.

A new era in regenerative medicine

This breakthrough symbolizes more than a lab experiment. It reflects:

  • Advances in stem cell biology
  • Precision biofabrication
  • Tissue vascular engineering
  • Cross disciplinary collaboration

Science is not just extending life. It is redefining what is biologically possible.

Final thoughts

The phrase kidney grown successfully should be understood accurately. Scientists have successfully grown functional kidney tissue capable of filtration in laboratory environments. They have engineered structures that mimic real kidney behavior. They have demonstrated perfusion and urine like output under controlled conditions.

But a complete, transplant ready, fully mature human kidney grown entirely in a lab is still under development.

Even so, this progress represents hope in action. For millions waiting for dialysis freedom. For families searching for donor matches. For a future where organ failure does not mean lifelong dependence on machines.

Regenerative medicine is not about hype. It is about steady, measurable scientific advancement.

And for the first time in history, building a human kidney is no longer impossible.


Research articles and references, for further deep dives

Kidney organoid development

  • Takasato et al, “Kidney organoids from human iPS cells contain multiple lineages” (Nature, 2015) — seminal work showing human pluripotent stem cells can form kidney-like structures.
  • Morizane & Bonventre, “Kidney Organoids: A Translational Journey” (Trends in Molecular Medicine) — review of organoid models and relevance to human disease.
  • McMahon, “Recent Advances in Kidney Development, Organoid Generation and Regeneration” — discusses developmental biology insights applied to organ engineering.

Scaffolding and tissue engineering

  • Ross et al, “Decellularized kidney scaffolds: an engineering and biological perspective” — exploration of using decellularized matrices for organ regeneration.
  • Song et al, “Regeneration and Experimental Orthotopic Transplantation of a Bioengineered Kidney” (Nature Medicine, 2013) — early proof-of-concept for bioengineered organ transplants in animals.

3D bioprinting and vascularization

  • Homan et al, “Bioprinting of 3D kidney tissues with integrated vasculature” — describes methods for printing kidney-like tissues with flow channels.
  • Zhang & Yu, “Engineering of Kidney Tissue with Vascular Networks” (Advanced Healthcare Materials) — focus on microvascular networks integration.

Reviews and clinical perspectives

Regenerative medicine for kidneys

  • Little et al, “Human Kidney Organoids: Progress and Challenges” (Cell Stem Cell) — comprehensive review of organoid potential and limitations.
  • Humphreys, “Mechanisms of Renal Regeneration” (Annual Review of Physiology) — context on kidney healing mechanisms important for engineering.
  • Campbell & Humphreys, “Regenerative Therapies for Kidney Disease” (Nature Reviews Nephrology) — clinical implications and future directions.

Bioprinting and tissue fabrication

  • Derby, “Printing and Prototyping of Tissues and Organs” (Science) — overview of 3D bioprinting approaches.
  • Mandrycky et al, “3D Bioprinting for Engineering Complex Tissues” (Biotechnology Advances) — broader context on fabrication technologies.

Journals with active contributions

These journals frequently publish research on kidney regeneration, organoids, stem cells, and tissue engineering:

  • Nature Biotechnology
  • Cell Stem Cell
  • Science Translational Medicine
  • Tissue Engineering
  • Biomaterials
  • BMC Nephrology
  • Nature Reviews Nephrology
  • Journal of the American Society of Nephrology

Searching within these titles for terms such as kidney organoid stem cell, bioprinting renal tissue, and bioengineered kidney vascularization yields many relevant studies.

Key institutional and clinical resources

Academic labs & research groups

  • Harvard Stem Cell Institute (HSCI) — kidney organoid research and pluripotent stem cell differentiation.
  • University of California Davis Regenerative Medicine Program — organ engineering and translational models.
  • Wyss Institute at Harvard — bioprinting and organ-on-chip platforms.

Clinical and translational centers

  • KidneyX Innovation Accelerator (NIH + ASN initiative) — focused on disruptive technologies in kidney care.
  • Regenerative Medicine Centres in major universities (Stanford, MIT, UCSF) — regularly host lectures, webinars, and open access publications.

Theses and textbooks

For structured learning, consult these texts:

  • Textbook of Organ Transplantation — chapters on tissue engineering and organ replacement strategies.
  • Regenerative Medicine and Tissue Engineering handbooks — comprehensive background on scaffolds, cells, growth factors, and manufacturing.

Useful search terms for deep literature dives

Use these queries on academic databases (PubMed, Google Scholar, Web of Science):

  • kidney organoid human iPS cells
  • decellularized kidney scaffold transplantation
  • 3D bioprinting vasculature renal tissue
  • functional kidney tissue engineering review
  • bioartificial kidney device clinical trial

Databases and filtering tips

PubMed

  • Start with broad phrases like kidney organoid kidney bioengineering then refine by year to capture the latest work.

ClinicalTrials.gov

  • Many regenerative strategies progress through preclinical and early clinical phases; searching for bioengineered kidney, kidney tissue scaffold, or renal cell therapy shows ongoing studies.
  • YouTube talks from major conferences (e.g., ISSCR, ASN Kidney Week, TERMIS) on organoid technology.
  • Recorded seminars from universities on stem cell based therapies.

Kidney organoid development & functional models

🔹 “Application progress of bio-manufacturing technology in kidney organoids”
A 2025 review covering organoid models, vascularization challenges, organ-on-chip and 3D printing technology as they apply to kidney organoids. This is a very current overview of where the field stands in biofabrication and functional tissue growth.

🔹 “Kidney Organoids: Current Advances and Applications”
A comprehensive review (2025) on the state of kidney organoid research, summarising differentiation, structure and functional relevance as research tools for modeling kidney development and disease.

🔹 “Recent advances in extracellular matrix manipulation for kidney organoid research”
Looks at how manipulating the extracellular matrix affects organoid development, structure, and function — an important step toward making more mature, functional tissues.

🔹 “Translating Organoids into Artificial Kidneys”
An accessible paper reviewing how organoids could become functional engineered kidneys, including barriers to clinical translation.

Engineering, bioprinting & tissue fabrication

🔹 “A review of 3D bioprinting for organoids”
Discusses 3D bioprinting technologies, bioinks, and the potential of printed organoids to model organ functions.

🔹 “Renal tissue engineering for regenerative medicine using polymers and hydrogels”
Explores biomaterials used in kidney tissue engineering and how they support cell growth and kidney-like structure formation.

🔹 “A critical review of current progress in 3D kidney biomanufacturing”
A review of 3D biomanufacturing for kidneys, exploring current limitations and why full organ fabrication is still in early stages.

Vascularization studies

🔹 “Strategies for improving vascularization in kidney organoids”
A detailed open-access review on how researchers are trying to induce blood vessel formation within kidney organoids — one of the biggest obstacles to making mature functional organs.

🔹 “Stem cell-derived kidney organoids: engineering the vasculature”
A foundational review on approaches to vascularise organoids to improve maturation and potential clinical relevance.

Cutting edge research example

🔹 “Engineering scalable vascularized kidney organoids” (npj Biomedical Innovations)
A recent experimental study showing methods to produce large numbers of vascularised nephron structures — a practical step toward tissue that could one day be implantable.

Academic databases

  • PubMed / PubMed Central — search terms to try: “kidney organoid functional development”, “renal tissue engineering review”, “3D printing vascularised tissue”, “bioengineered kidney translational research”

Practical tips for your deep dive

📌 Start with recent reviews (2024-2025) like the kidney organoid progress and bio-manufacturing application papers above to get context on limitations and opportunities for translation.

📌 Pair reviews with a few experimental studies such as scalable vascular organoid research — this bridges theory and practice.

📌 Track citations out from key papers — often the most valuable sources are cited works that you discover through reviews.

Spread the love
Continue Reading

Technology

Artificial intelligence (AI) and machine learning (ML) in the field of cancer treatment

Published

on

Artificial intelligence AI and machine learning ML in the field of cancer treatment

Especially in the areas of diagnosis and treatment, artificial intelligence (AI) and machine learning (ML) have the potential to change the field of cancer research. AI and ML are able to find patterns and insights in vast amounts of data that may not be immediately obvious to human researchers.

Image analysis is one use of AI and ML in the field of cancer research. AI can analyse medical pictures like X-rays, CT scans, and MRIs to find malignant tumours and other anomalies by utilising deep learning algorithms. This might result in earlier cancer detection and help doctors make more accurate diagnoses.

By facilitating the analysis of enormous amounts of data, artificial intelligence (AI) has the potential to transform the area of cancer research by enabling the analysis of vast amounts of data, speeding up the discovery of new therapies, and improving patient outcomes. There are several ways in which AI is being used in cancer research, including: 

  • Image analysis: AI algorithms can be used to analyze medical images, such as X-rays and CT scans, to identify signs of cancer and monitor its progression. This can help to diagnose cancer at an early stage and track its response to treatment. 
  • Drug discovery: AI can be used to analyze large amounts of data to identify new targets for drug development and to optimize the design of drugs to maximize their efficacy and minimize side effects. 
  • Predictive analytics: AI algorithms can be trained on large datasets to predict patient outcomes and to identify patients who are most likely to respond to a particular therapy. This information can be used to personalize treatment plans and improve patient outcomes. 
  • Clinical trial design: AI can be used to analyze patient data and identify patients who are most likely to participate in clinical trials, which can speed up the development of new therapies. 

There have been several successful case studies of AI in cancer research, including the development of new drugs for the treatment of lung and breast cancer, as well as the development of algorithms for early cancer detection and personalized treatment planning. 

AI and ML are being used in cancer research for drug discovery and development. AI can analyze large amounts of data, such as genetic and protein information, to identify potential drug targets and predict how different compounds will interact with the body. This can help speed up the drug development process and increase the chances of success. AI and ML are also being used to analyze patient data, including medical records, imaging, and genomics data, to identify patterns and insights that can help in the personalized treatment of cancer. This can help doctors make more informed treatment decisions and improve patient outcomes. 

It’s important to note that AI and ML in cancer research are still in their early stages and there are still many challenges to be overcome. These include the need for large amounts of high-quality data to train the models, the need for robust validation methods and the need to address ethical and legal issues. AI and ML have the potential to revolutionize cancer research, particularly in the areas of diagnosis and treatment. They can be used for image analysis, drug discovery and development, and personalized treatment. However, more research is needed to overcome the challenges and ensure that these technologies can be used safely, ethically, and effectively in the fight against cancer. 

 5,351 total views,  1 views today

Spread the love
Continue Reading

Editor's Picks

Antineoplaston can be used as an alternative treatment for cancer – part 2/2

Published

on

Antineoplaston can be used as an alternative treatment for cancer part 2

Read part 1 before continuing part 2

Antineoplastons are a group of naturally occurring peptides and amino acid derivatives that have been proposed as a treatment for cancer. The theory behind antineoplaston therapy is that these compounds can selectively target and kill cancer cells while leaving healthy cells unharmed. 

Antineoplaston therapy was first developed by Dr. Stanislaw Burzynski in the 1970s. Dr. Burzynski discovered the compounds while studying peptides in blood and urine, and he began using them to treat cancer patients in the 1980s. Over the years, Dr. Burzynski and his team have conducted multiple clinical trials to test the safety and efficacy of antineoplaston therapy. 

The results of these trials have been mixed. Some patients have reported significant improvements in their cancer symptoms, while others have not seen any benefit. Additionally, some studies have suggested that antineoplaston therapy may have toxic side effects. The American Cancer Society (ACS) states that the safety and effectiveness of antineoplaston therapy have not been proven. The FDA has approved a limited number of clinical trials for antineoplastons for specific types of brain tumors, but larger and well-designed studies are still needed to confirm the safety and efficacy of antineoplaston therapy. 

It’s worth noting that Antineoplaston therapy is not widely accepted in the medical community, and the scientific evidence supporting its use as a cancer treatment is limited. The FDA has not approved antineoplaston therapy as a treatment for cancer, and it is not widely available in the United States. 

Antineoplaston therapy is an alternative cancer treatment that has been proposed as a treatment for cancer, but its safety and effectiveness have not been proven. There are still many questions about the long-term safety and efficacy of antineoplaston therapy, and more research is needed to determine whether it is a viable treatment option for cancer patients. Patients should consult with their healthcare providers before considering antineoplaston therapy as a cancer treatment. It’s important to remember that while alternative therapies may have some positive effects, they may not be as effective as standard cancer treatments and may have negative side effects. 

 13,627 total views,  7 views today

Spread the love
Continue Reading

Trending